Navigation Links
Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 5
Date:11/2/2009

SEATTLE, Nov. 2 /PRNewswire-FirstCall/ -- On Thursday, November 5, 2009, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific, members of Cell Therapeutics, Inc.'s (CTI) (Nasdaq and MTA: CTIC) management team will host a conference call to discuss the Company's 2009 third quarter financial results.

    Conference Call Numbers
    Thursday, November 5
    8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time
    1-877-941-6010 (US Participants)
    1-1-480-629-9772 (International)

    Call-back numbers for post-call listening available at 10:30 a.m. Eastern:
    1-800-406-7325 (US Participants)
    1-303-590-3030 (International)
    Passcode: 4168724#

    Live audio webcast at www.celltherapeutics.com will be archived for
    post-call listening approximately two hours after the call ends.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    F: 206.272.4434
    E: deramian@ctiseattle.com
    www.celltherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.celltherapeutics.com/investors

SOURCE Cell Therapeutics, Inc.


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split
2. Cell Therapeutics, Inc. Annual Meeting of Shareholders Scheduled for Tuesday, October 20, 2009
3. Oxygen Biotherapeutics, Inc. to Present at Investor Conferences in Zurich
4. Oxygen Biotherapeutics, Inc. Posts Blog by CEO Chris Stern on Proposed Reverse Split
5. Cell Therapeutics, Inc.s (CTI) Presentation at BioCentury NewsMakers Conference to be Webcast
6. Oxygen Biotherapeutics, Inc. Posts Latest Blog by CEO Chris Stern
7. Cell Therapeutics, Inc.s (CTI) Rodman & Renshaw Healthcare Conference Presentation to be Webcast
8. Oxygen Biotherapeutics, Inc. to Begin Oxycyte(R) Phase II Clinical Trials in Switzerland
9. Rx for Africa, Inc. and Zirus, Inc. Create Joint Venture, ZiRx Therapeutics, Ltd.
10. Cell Therapeutics, Inc. (CTI) to Report Second Quarter Financial Results on August 6
11. Cell Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Warrants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Back Pain Centers ... back pain with a reputable physician in their area, announces the launch of a ... information for patients who are looking for reputable physicians to help them with back ...
(Date:4/25/2017)... (PRWEB) , ... April 25, 2017 , ... ... addition of predictive analytics to its patient care management module. Using this new ... before a patient has been initiated on continuous positive airway pressure (CPAP), oral, ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® ... introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky ... horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... 2017 , ... Ridgecrest Herbals makes it a point to lead the Utah ... and support renewable energy. They believe this is a crucial part of their mission ... health issues, and maintain that destroying the environment in the pursuit of profit is ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology: